GlassScriptPhysician profile
Robert L Ordonez
NPI 1740375880
$19,246.63
in general payments reported to CMS, 2019-2025
54 companies · $2,685 in 2025
The $2,685 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,933 · 2020: $2,176 · 2021: $2,339 · 2022: $1,254 · 2023: $7,487 · 2024: $1,372 · 2025: $2,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,264 · Food and Beverage: $5,013 · Travel and Lodging: $1,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,264.00 |
| Food and Beverage | $5,013.23 |
| Travel and Lodging | $1,266.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,049.54 | 2019-2025 | |
| Abbvie INC. | $1,587.79 | 2021-2025 | |
| Amgen INC. | $1,411.45 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,195.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $780.64 | 2019-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $443.93 | 2019-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $413.62 | 2019-2025 | |
| Allergan, INC. | $390.75 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $370.83 | 2020-2022 | |
| Radius Health, INC. | $355.70 | 2019-2025 | Tymlos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $350.57 | 2025 | Caplyta |
| Pfizer INC. | $341.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $312.53 | 2021-2025 | |
| Axsome Therapeutics, INC. | $299.91 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $261.02 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ordonez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.